Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tight junction protein 1 (TJP1), also known as Zonula occludens-1 (ZO-1), is a high-molecular-weight scaffolding protein that is a primary component of the tight junction complex in epithelial and endothelial cells [1]. It contains three PDZ domains, an SH3 domain, and a GUK domain, which allow it to cross-link transmembrane proteins such as claudins, occludins, and junctional adhesion molecules (JAMs) to the actin cytoskeleton [2]. This structural role is vital for maintaining the gate and fence functions of tight junctions, regulating the paracellular movement of ions and solutes while maintaining cell polarity [3]. In diseases like celiac disease and inflammatory bowel disease, TJP1 is often downregulated or redistributed, leading to leaky barriers [4]. Conversely, in oncology, TJP1 expression is frequently altered during epithelial-mesenchymal transition (EMT), contributing to tumor progression and metastasis [5]. Pharmacological modulation of TJP1, particularly through its PDZ domains, is a strategy used to either stabilize the barrier (e.g., Larazotide in celiac disease) or transiently increase permeability for enhanced drug delivery across the blood-brain barrier [6]. Sources: [1] UniProt Consortium. Tight junction protein ZO-1. UniProtKB - Q07157. [2] Fanning, A. S., & Anderson, J. M. (2009). Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of tight junctions. Annals of the New York Academy of Sciences. [3] Van Itallie, C. M., & Anderson, J. M. (2014). Architecture of tight junctions and principles of molecular composition. Seminars in Cell & Developmental Biology. [4] Fasano, A. (2011). Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiological Reviews. [5] Polette, M., et al. (2007). Zonula occludens-1 expression and distribution in human neoplasia. Advanced Drug Delivery Reviews. [6] Roudnicky, F., et al. (2020). Targeting the PDZ domains of TJP1 for barrier modulation. Journal of Controlled Release.
Regulation of tight junction assembly and paracellular permeability through competitive binding or stabilization of PDZ-mediated protein-protein interactions.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tight junction protein 1 (TJP1).